Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy.
about
Anti-CD19 Monoclonal Antibodies: a New Approach to Lymphoma TherapyCD19 as an attractive target for antibody-based therapyAdvances in anticancer immunotoxin therapyDesign and applications of bispecific heterodimers: molecular imaging and beyondBioengineering a unique deimmunized bispecific targeted toxin that simultaneously recognizes human CD22 and CD19 receptors in a mouse model of B-cell metastases.A new drug delivery method of bispecific ligand-directed toxins, which reduces toxicity and promotes efficacy in a model of orthotopic pancreatic cancer.Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies.A novel bispecific ligand-directed toxin designed to simultaneously target EGFR on human glioblastoma cells and uPAR on tumor neovasculature.Phase I study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies.Targeting tumor-initiating cancer cells with dCD133KDEL shows impressive tumor reductions in a xenotransplant model of human head and neck cancerTreatment of hematologic malignancies with immunotoxins and antibody-drug conjugates.A novel bispecific immunotoxin delivered by human bone marrow-derived mesenchymal stem cells to target blood vessels and vasculogenic mimicry of malignant gliomas.Immunotherapy targets in pediatric cancer.Mutagenic Deimmunization of Diphtheria Toxin for Use in Biologic Drug Development.A novel reduced immunogenicity bispecific targeted toxin simultaneously recognizing human epidermal growth factor and interleukin-4 receptors in a mouse model of metastatic breast carcinoma.Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activityTargeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression.Hemangiosarcoma and its cancer stem cell subpopulation are effectively killed by a toxin targeted through epidermal growth factor and urokinase receptors.Immunotoxins for leukemia.The use of single chain Fv as targeting agents for immunoliposomes: an update on immunoliposomal drugs for cancer treatment.Emerging small molecule and biological therapeutic approaches for the treatment of autoimmunity.Targeted toxins in brain tumor therapy.Dual targeting strategies with bispecific antibodies.Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia.Multi-specific antibodies for cancer immunotherapy.A bispecific EpCAM/CD133-targeted toxin is effective against carcinomaEngineering a CD123xCD3 bispecific scFv immunofusion for the treatment of leukemia and elimination of leukemia stem cells.Novel therapy for childhood acute lymphoblastic leukemia.Intracranial elimination of human glioblastoma brain tumors in nude rats using the bispecific ligand-directed toxin, DTEGF13 and convection enhanced delivery.CD40 ligand is necessary and sufficient to support primary diffuse large B-cell lymphoma cells in culture: a tool for in vitro preclinical studies with primary B-cell malignanciesIL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced FunctionThe emerging therapeutic role of antibody mixtures.Development of a Deimmunized Bispecific Immunotoxin dDT2219 against B-Cell Malignancies.
P2860
Q26775363-37DE8911-F07A-4501-B289-67FAF35263E0Q27011836-37B797EC-B259-4966-A043-CAF30381EC9AQ28085551-080D36FA-AC52-4204-AC52-5026C8FF9D3EQ33732587-52B79FCD-65D7-41D2-8196-666950A14ABDQ33907691-186429D3-FC83-4C0B-AE0B-38C5BB245A26Q34009357-FA47DB03-1577-4E82-B981-CC99D1685A0CQ34548319-496B8098-DBFD-47B0-AC6B-5C6F06D79A69Q34993336-30CE7DFB-A112-4E14-B63B-6CFF126E9AE0Q35180101-8FA6BA1D-2637-46A8-B489-C69DD1599DF1Q35317540-96C17029-8458-403E-8098-0A9E1ABC97F1Q35446333-CB93C89C-1F48-4398-B7BE-0716FF80496DQ35746801-360C9102-4C32-4D67-891E-29D90C668D88Q35971029-4434062D-7F2B-49B4-8E7B-AD0A9B73A092Q36226862-69DBFC92-1BBF-4128-9059-9D3CBA8AB75FQ37373289-936BEE8A-9DD5-4716-9D18-FD6DC799259EQ37400550-CC1E7640-4C2B-4475-AAEB-4212EC5C9229Q37532147-C625912F-4E39-4952-9345-4CA9803BD853Q37700709-323CF09C-FC9B-43CA-8644-2A3C71E7E96EQ37709336-C824011E-0057-42C1-9E6C-A08256F49C96Q37717652-7FF9C8D9-B1B7-42B9-9E04-DE523803AB11Q37813704-1FEEA7D2-64B7-4CDC-9527-9E0973276457Q37954275-3913899E-2ED7-4849-9A26-7E72C50E6F5BQ37997559-E03DCD5E-1D47-4907-A446-889F7CB48D9FQ38068494-FB95A9F1-1C79-43BD-BFBB-CEAD6D9CB30CQ38196723-E3AC6FAB-EA9E-4478-A5C3-6EDED7F832CAQ38867217-0F86EC49-7F00-420F-902B-EB89CD6833C6Q39323781-F3480725-B02F-438F-92F8-660FA85D5C3DQ39368957-4786CEE0-4F55-4391-925A-6EEAD00412ABQ39839534-BC0D8533-C0EA-4F90-ABC6-65C448BC9492Q42126275-1FABF94B-00E6-416A-9B72-174ABA6DDD9AQ42134875-E6A23A3E-279A-4226-B219-5FDB0B6AF7FDQ46026271-EE82A288-7979-46BF-8C4A-86DA658F5EC2Q49540233-6C769652-2F5E-4057-B303-D0CFCC4FC693
P2860
Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 26 March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Genetic alteration of a bispec ...... st systemic B cell malignancy.
@en
Genetic alteration of a bispec ...... st systemic B cell malignancy.
@nl
type
label
Genetic alteration of a bispec ...... st systemic B cell malignancy.
@en
Genetic alteration of a bispec ...... st systemic B cell malignancy.
@nl
prefLabel
Genetic alteration of a bispec ...... st systemic B cell malignancy.
@en
Genetic alteration of a bispec ...... st systemic B cell malignancy.
@nl
P2093
P2860
P1433
P1476
Genetic alteration of a bispec ...... st systemic B cell malignancy.
@en
P2093
Andrew R Sicheneder
Daniel A Vallera
Elizabeth P Taras
P2860
P304
P356
10.1016/J.LEUKRES.2009.02.006
P577
2009-03-26T00:00:00Z